Details for Patent: 5,852,027

Title:	Antiviral 1,3-dioxolane nucleoside analogues
Abstract:	This invention includes the compounds 2'-deoxy-5-fluoro-3'-oxacytidine, (-)-2'-deoxy-5-fluoro-3'-oxacytidine, and (+)-2'-deoxy-5-fluoro-3+-oxacytidine, and pharmaceutically acceptable salts thereof for use in medical therapy, for example for the treatment or prophylaxis of an HIV infection.
Inventor(s):	Liotta; Dennis C. (McDonough, GA), Schinazi; Raymond F. (Decatur, GA), Choi; Woo-Baeg (North Brunswick, NJ)
Assignee:	Emory University (Atlanta, GA)
Filing Date:	Nov 09, 1993
Application Number:	08/150,012
Claims:	1. (.+-.)-2'-Deoxy-5-fluoro-3'-oxacytidine. 2. (-)-.beta.-2'-Deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer. 3. (+)-.beta.-2'-Deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer. 4. A pharmaceutical composition that comprises 2'-deoxy-5-fluoro-3'-oxacytidine, its (-) or (+) enantiomer or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier. 5. A method for the treatment of HIV infection in human cells, comprising administering an HIV-effective amount of .beta.-2'-deoxy-5-fluoro-3'-oxacytidine or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier. 6. A method for the treatment of HIV infection in human cells, comprising administering an HIV-effective amount of (+)-.beta.-2'-deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier. 7. A method for the treatment of HIV infection in human cells, comprising administering an HIV-effective amount of (-)-.beta.-2'-deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier.